Please provide your email address to receive an email when new articles are posted on . Use of a single inhaler with albuterol and corticosteroids as needed reduced exacerbations by 26%. As-needed ...

Please provide your email address to receive an email when new articles are posted on . The meta-analysis included 27 unique randomized controlled trials and 50,496 patients. Combinations improved ...

AstraZeneca already has its aging two-drug inhaler Symbicort as a maintenance treatment for asthma. Now, with a pair of trial wins, the company looks on track to have a novel doublet for controlling ...

BOSTON -- Inhaled corticosteroids (ICS) combined either with formoterol (Foradil) or short-acting beta-agonists (SABA) for asthma treatment were associated with reduced risks of severe exacerbations ...

Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

“Be wary of [SABA] overuse. It is for when the patient has poor control of their symptoms, but should not be used for routine treatment,” said Holmes, a general practitioner (GP) partner at The Park ...

Asthma management guidelines advocate a stepwise approach to asthma therapy, including the addition of a long-acting bronchodilator to inhaled steroid therapy at step 3. This is almost exclusively ...

These findings challenge national and international medical guidelines, particularly in the USA, where this approach has yet to be approved. Despite effective drug treatment options, most adults with ...

Researchers found no evidence that initiation of inhaled corticosteroids or leukotriene receptor antagonist therapy is associated with fewer wheezing/asthma attacks than therapy with a short-acting ...

I really didn't see the death of short-acting beta-agonists (SABAs) coming. Sure, I'd read the SYGMA trials, [1,2] and yes, I was aware of lobbying from the "other side of the pond" (Europe). [3] So I ...